Tudor Investment Corp Et Al Takes Position in Pacific Biosciences of California (PACB)

Tudor Investment Corp Et Al purchased a new position in shares of Pacific Biosciences of California (NASDAQ:PACB) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 78,879 shares of the company’s stock, valued at approximately $300,000. Tudor Investment Corp Et Al owned approximately 0.09% of Pacific Biosciences of California at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new position in shares of Pacific Biosciences of California during the fourth quarter worth about $1,878,000. Moloney Securities Asset Management LLC acquired a new position in shares of Pacific Biosciences of California during the fourth quarter worth about $128,000. Levin Capital Strategies L.P. boosted its position in shares of Pacific Biosciences of California by 600.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,043,709 shares of the company’s stock worth $3,966,000 after buying an additional 894,627 shares during the period. Arrowpoint Asset Management LLC boosted its position in shares of Pacific Biosciences of California by 57.4% in the fourth quarter. Arrowpoint Asset Management LLC now owns 1,471,554 shares of the company’s stock worth $5,592,000 after buying an additional 536,594 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its position in shares of Pacific Biosciences of California by 44.0% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 30,231 shares of the company’s stock worth $115,000 after buying an additional 9,240 shares during the period. 69.17% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) opened at 4.71 on Tuesday. Pacific Biosciences of California has a one year low of $3.76 and a one year high of $10.75. The stock’s market capitalization is $436.73 million. The firm has a 50-day moving average of $4.95 and a 200 day moving average of $6.60.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings results on Thursday, February 2nd. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. The firm had revenue of $25.70 million for the quarter, compared to analysts’ expectations of $22.84 million. Pacific Biosciences of California had a negative net margin of 81.99% and a negative return on equity of 75.50%. The business’s revenue for the quarter was down 29.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.02) earnings per share. On average, equities research analysts anticipate that Pacific Biosciences of California will post ($0.88) earnings per share for the current fiscal year.

Your IP Address:

A number of brokerages recently issued reports on PACB. Cantor Fitzgerald reissued a “buy” rating and set a $8.00 price target on shares of Pacific Biosciences of California in a research report on Friday, February 3rd. Zacks Investment Research raised shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a report on Tuesday, November 29th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Pacific Biosciences of California currently has an average rating of “Buy” and a consensus price target of $11.27.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company’s Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System.

5 Day Chart for NASDAQ:PACB

Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California (NASDAQ:PACB).

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024766/tudor-investment-corp-et-al-takes-position-in-pacific-biosciences-of-california-pacb.html

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.